Phase II Evaluation of Liposomal Doxorubicin with Docetaxel in Patients with Metastatic Breast Cancer. (Record no. 21804012)
[ view plain ]
000 -LEADER | |
---|---|
fixed length control field | 00867 a2200241 4500 |
005 - DATE AND TIME OF LATEST TRANSACTION | |
control field | 20250516093255.0 |
008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
fixed length control field | ####s 0 0 eng d |
022 ## - INTERNATIONAL STANDARD SERIAL NUMBER | |
International Standard Serial Number | 1661-3791 |
024 7# - OTHER STANDARD IDENTIFIER | |
Standard number or code | 10.1159/000272119 |
Source of number or code | doi |
040 ## - CATALOGING SOURCE | |
Original cataloging agency | NLM |
Language of cataloging | eng |
Transcribing agency | NLM |
100 1# - MAIN ENTRY--PERSONAL NAME | |
Personal name | Fasano, Julie |
245 00 - TITLE STATEMENT | |
Title | Phase II Evaluation of Liposomal Doxorubicin with Docetaxel in Patients with Metastatic Breast Cancer. |
Medium | [electronic resource] |
260 ## - PUBLICATION, DISTRIBUTION, ETC. | |
Name of publisher, distributor, etc. | Breast care (Basel, Switzerland) |
Date of publication, distribution, etc. | Mar 2010 |
300 ## - PHYSICAL DESCRIPTION | |
Extent | 17-21 p. |
Other physical details | digital |
500 ## - GENERAL NOTE | |
General note | Publication Type: Journal Article |
700 1# - ADDED ENTRY--PERSONAL NAME | |
Personal name | Hershman, Dawn |
700 1# - ADDED ENTRY--PERSONAL NAME | |
Personal name | Novik, Yelena |
700 1# - ADDED ENTRY--PERSONAL NAME | |
Personal name | Levinson, Benjamin |
700 1# - ADDED ENTRY--PERSONAL NAME | |
Personal name | Blozie, Kim |
700 1# - ADDED ENTRY--PERSONAL NAME | |
Personal name | Tiersten, Amy D |
773 0# - HOST ITEM ENTRY | |
Title | Breast care (Basel, Switzerland) |
Related parts | vol. 5 |
-- | no. 1 |
-- | p. 17-21 |
856 40 - ELECTRONIC LOCATION AND ACCESS | |
Uniform Resource Identifier | <a href="https://doi.org/10.1159/000272119">https://doi.org/10.1159/000272119</a> |
Public note | Available from publisher's website |
No items available.